Pearl Diagnostics
Stub active Updated Apr 26, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
About
Pearl Diagnostics is a Baltimore-based biotech and Johns Hopkins University spinout founded in 2014, developing a noninvasive fungal infection test 1. CEO Eric Gornstein noted “It’s extraordinarily rare for a company at the Series A level to have a commercial product,” highlighting the company’s advanced commercial stage 1. The Series A proceeds will be used to launch US sales following recent FDA clearance and expand into Europe, where Pearl has secured CE approval 1.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-04-24 | Series A | $11.2M | Undisclosed | Undisclosed 1 |
What Investors Say
No independently sourced investor quotes found.
What Founders Say
CEO Eric Gornstein on the company’s commercial readiness at Series A: “It’s extraordinarily rare for a company at the Series A level to have a commercial product.” 1